Financial Security Advisor Inc. Raises Position in Hologic, Inc. (NASDAQ:HOLX)

Financial Security Advisor Inc. lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 33.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,311 shares of the medical equipment provider’s stock after acquiring an additional 836 shares during the quarter. Financial Security Advisor Inc.’s holdings in Hologic were worth $239,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. State Street Corp increased its holdings in Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the period. FMR LLC increased its stake in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after acquiring an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after acquiring an additional 195,285 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Down 1.8 %

Shares of NASDAQ:HOLX opened at $63.21 on Friday. Hologic, Inc. has a 1-year low of $62.69 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market cap of $14.18 billion, a P/E ratio of 19.94, a P/E/G ratio of 2.14 and a beta of 0.97. The firm has a fifty day moving average price of $69.33 and a 200 day moving average price of $76.10.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of analyst reports. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Royal Bank of Canada cut their price target on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. JPMorgan Chase & Co. increased their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Raymond James restated an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.